TSS
RAPT

Two Sigma Securities’s RAPT Therapeutics RAPT Stock Holding History

Two Sigma Securities’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,323
Closed -$12.9K – 1979
2025
Q1 		$12.9K Buy
+1,323
New +$13K ﹤0.01% 1180
2021
Q3 		– Sell
-984
Closed -$250K – 1871
2021
Q2 		$250K Buy
+984
New +$184K 0.01% 1125

Other funds holding RAPT

MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Two Sigma Securities's RAPT Position: Q2 2025 in Review

Two Sigma Securities sold out of RAPT Therapeutics (RAPT) in Q2 2025, closing a stake of 1,323 shares — an estimated $12.9K sold.

Two Sigma Securities first reported a position in RAPT in Q2 2021 and held it in 2 quarters. The position peaked at $250K in Q2 2021. 50 funds tracked by Wall St. Rank hold RAPT as of Q2 2025.

  • Two Sigma Securities reported no remaining RAPT Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Securities sold 1,323 RAPT Therapeutics shares in Q2 2025, an estimated $12.9K.
  • Two Sigma Securities first reported a position in RAPT Therapeutics in Q2 2021 and held it in 2 quarters.
  • Two Sigma Securities's RAPT Therapeutics position peaked at $250K in Q2 2021.
  • 50 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2025.

Based on Two Sigma Securities's 13F filing for Q2 2025, filed 14 Aug 2025.